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Abstract
Background: The activation of the members of the myocyte enhancer factor-2 family (MEF2A, B, C and D) of transcription
factors promotes cardiac hypertrophy and failure. However, the role of its individual components in the pathogenesis of
cardiac hypertrophy remains unclear.
Methodology/Principal Findings: In this study, we investigated whether MEF2C plays a role in mediating the left ventricular
hypertrophy by pressure overload in mice. The knockdown of myocardial MEF2C induced by specific small interfering RNA
(siRNA) has been shown to attenuate hypertrophy, interstitial fibrosis and the rise of ANP levels in aortic banded mice. We
detected that the depletion of MEF2C also results in lowered levels of both PGC-1a and mitochondrial DNA in the
overloaded left ventricle, associated with enhanced AMP:ATP ratio. Additionally, MEF2C depletion was accompanied by
defective activation of S6K in response to pressure overload. Treatment with the amino acid leucine stimulated S6K and
suppressed the attenuation of left ventricular hypertrophy and fibrosis in the aforementioned aortic banded mice.
Conclusion/Significance: These findings represent new evidences that MEF2C depletion attenuates the hypertrophic
responses to mechanical stress and highlight the potential of MEF2C to be a target for new therapies to cardiac hypertrophy
and failure.
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Introduction
Hypertrophy is a common feature of many forms of heart
disease. While initially an adaptive response to increased workload
and injury, in the long term cardiac hypertrophy predisposes to
heart failure[1,2,3]. At the cellular level, myocardial hypertrophy
is characterized by distinct accumulation of myofibrillar proteins
and organelles in cardiomyocytes, while the development of heart
failure is accompanied by degeneration and loss of hypertrophic
cardiomyocytes as well as interstitial fibrosis[4]. In a current view,
the hypertrophy and degeneration of cardiomyocytes represent a
continuum governed by patterns of beneficial and adverse
signaling triggered by stimuli such as mechanical stress and
neurohumoral factors[5,6,7].
Among the intracellular pathways that integrate mechanical
and hormonal signals, MEF2 (myocyte enhancer factors-2, members A
to D) transcription factors play prominent roles in the regulation of
cardiac hypertrophy and remodeling[8,9,10]. In this context,
many studies have shown that overall MEF2 DNA-binding activity
is enhanced in cardiomyocytes in response to biomechanical and
neurohormonal stimuli[11,12,13]. Overexpression of MEF2A or
MEF2C in cultured cardiomyocytes induces sarcomere degener-
ation and cardiomyocytes elongation, suggesting that activation of
these members may compose signaling pathways responsible for
pathologic hypertrophy [8]. Accordingly, forced expressions of
MEF2A, C and D in mice heart were demonstrated to be sufficient
to drive intolerance to pressure overload, ventricular chamber
dilation and contractile dysfunction[8,9,10]. There is also evidence
associating MEF2 transcription factors with common forms of
human heart failure[14]. Furthermore, the transgenic expression
of negative dominants of MEF2 was shown to prevent chamber
dilation and mechanical dysfunction, with minor effects on cardiac
growth in calcineurin-induced hypertrophy[9]. Recent studies
performed in mice with dominant-negative MEF2D suggested that
this factor is an important mediator of the pathologic left
ventricular hypertrophy, as these mice displayed no cardiac
hypertrophy, fibrosis or fetal gene activation in response to
pressure overload[10]. Altogether, these evidences support the
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8472idea that MEF2 factors mediate the effects of detrimental signaling
pathways in response to hypertrophic stimuli. Nevertheless, the
role of each specific MEF2 member, such as MEF2A or MEF2C,
in cardiac hypertrophy remains unclear mainly because of the
lethal cardiac phenotypes resulting from genetic deletions of these
members[15,16,17].
To define the potential function of MEF2C in the cardiac
responses to pressure overload we conceived a strategy to deplete
this factor in mouse heart by in vivo delivery of small interfering
(si)RNA. Left ventricular hypertrophy induced by aortic banding
in mice was used as a model system in this study.
Results
Optimization of Myocardial MEF2C Silencing by siRNA
As an initial approach, experiments were set to test the efficacy of
siMEF2C to knockdown MEF2C in cultured NRVMs (Neonatal
Rat Ventricular Myocytes). Transfection efficiency of siRNA in this
model system was previously assessed with fluorescent oligonucle-
otide[18] and was demonstrated to range around 80% in respect to
cells treated with the irrelevant siGFP (Green Fluorescent Protein).
Transfection of siMEF2C (300 ng/ml) reduced the MEF2C tran-
scripts in NRVMs by approximately 80% (Figure 1A). siMEF2C
had no influence in the amounts of MEF2A, MEF2B or MEF2D
transcripts (Figure 1B-D). Quantitative PCRs were normalized by
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase). An anti-
body that was specific to MEF2C recognized a protein with a
molecular weightcloseto 55KDawhile specificantibodyto MEF2A
recognized a protein at about 72KDa in the extracts of NRVMs.
Western blot analysis indicated that MEF2C was reduced in the
order of 75%, while no change could be observed in the expression
of MEF2A in cells treated with siMEF2C, in comparison with cells
treated with siGFP (Figure 1E, F). Immunoblottings with anti-
GAPDH antibody were used as control.
After the initial characterization in NRVMs, we then searched
for an amount of siMEF2C that, when injected systemically via the
jugular vein, could deplete myocardial MEF2C in mice left
ventricle. We started off with 450 mg/Kg of siMEF2C based on a
previous report[19] and observed an expressive reduction, of
about 85%, of myocardial MEF2C protein expression 1 day after
bolus injections of 900 mg/Kg of siMEF2C (Figure 2A). Injections
of siGFP (900 mg/Kg) did not affect MEF2C expression levels in
the left ventricle in comparison with phosphate buffer saline
(Figure 2B). The treatment with siMEF2C was accompanied by
marked reduction of MEF2C transcripts, but not of those from
MEF2A, MEF2B or MEF2D (Figure 2C-F), after normalization to
GAPDH. Reduction in MEF2C transcripts and protein levels was
also demonstrated to occur in banded mice treated with siMEF2C
(Figure 2F, G).
Complementary data on the ability of siMEF2C to deplete
MEF2C protein levels was obtained by analyzing isolated
cardiomyocytes. The expression of MEF2C was reduced in
Figure 1. MEF2C silencing in NRVMs culture. (A) Bar graph shows relative quantity (RQ) of MEF2C in respect to GAPDH transcripts as a
percentage of calibrator sample (siGFP) obtained by real time-PCR. (B) Bar graph shows the RQ of MEF2A transcripts. (C) Bar graph shows the RQ of
MEF2B transcripts. (D) Bar graph shows the RQ of MEF2D transcripts. (E) MEF2C protein expression (n=3 cultures). (F), MEF2A protein expression.
*p ,0.05 vs treatment with siGFP. These data are from 3 NRVMs culture at least.
doi:10.1371/journal.pone.0008472.g001
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PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8472Figure 2. Optimization of MEF2C silencing in mice left ventricle. (A) MEF2C protein expression from assays with increasing amounts of
siMEF2C or siGFP, via the jugular vein. (B) Myocardial expression of MEF2C from mice treated with siGFP and phosphate buffer saline (PBS). (C)
Relative quantity (RQ) of MEF2C, (D) MEF2A and (E) MEF2B transcripts in mice treated with 30 mg of siMEF2C or siGFP. (F) MEF2D transcripts in mice
treated with siMEF2C or siGFP. (G) Bar graphs show RQ of MEF2C transcript and (H) MEF2C protein expression in the left ventricle of aortic banded
(TAC) and sham-operated (SO) mice. (I) MEF2C protein expression in adult cardiomyocytes harvested from mice left ventricle 24 hours after siRNA
treatment. * p,0.05 vs SOsiGFP; # p,0.05 vs TACsiGFP. At least 6 animals were analyzed in these experiments.
doi:10.1371/journal.pone.0008472.g002
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treatment with siMEF2C to similar levels of myocardial extracts
(,75%), as depicted in Figure 2H.
We then set to address the time-course of MEF2C reduction in
the left ventricle obtained after systemically delivered siMEF2C. As
shown in Figure 3A, MEF2C protein expression was reduced by
approximately 75% in the left ventricle of control mice up to the 4
th
day after the administration of siMEF2C. However, by the 7
th day
after the siMEF2C myocardial MEF2C reached levels comparable
to those of mice treated with siGFP and remained unchanged
thereafter. Further analysis confirmed similar reductions in MEF2C
transcripts in the myocardium over time after the administration of
siMEF2C (Figure 3B). Signaling molecules potentially involved in
MEF2C activation[12,13,18] were also examined to exclude off-
target effects of siMEF2C. As shown in Figure 3C, no change was
detected in the myocardial levels of FAK (Focal Adhesion Kinase),
JNK (c-Jun N-Terminal Kinase) or Shp2 (Src homology region 2,
phosphatase 2) after treatment with siMEF2C.
The consequences of the treatment with siMEF2C in tissues
such as lung and kidney were analyzed. We found reductions of
MEF2C transcripts in the lung similar as to those of left ventricle
from mice treated with siMEF2C (Figure 3D). However, treatment
with siMEF2C did not change the amount of MEF2C transcripts
in the kidney. Overall, the results establish that siMEF2
administered via jugular vein can silence left ventricle MEF2C
protein levels, although it also depletes MEF2C in the lungs.
MEF2C Silencing Attenuates Load-Induced Hypertrophy
in Aortic Banded Mice
Next we investigated whether MEF2C silencing affects the load-
induced left ventricular hypertrophy. In this set of experiments
siMEF2C was intravenously injected in mice via jugular vein one
day before sham-operation or aortic banding. We found that
blood pressure, heart rate, left ventricular structure and function of
sham-operated mice were unaffected by siMEF2C, indicating that
depletion of MEF2C does not influence basal cardiac function or
Figure 3. Effects of siMEF2C in distinct tissues and signaling proteins. (A) Time-course of MEF2C protein expression and (B) transcript levels
normalized by GAPDH. (C) Myocardial expression of FAK, JNK, SHP2 and GAPDH. (D) Relative quantity of MEF2C transcripts in mice lung and kidney.
*p ,0.05 vs treatment with siGFP. At least 5 mice were employed for each subgroup.
doi:10.1371/journal.pone.0008472.g003
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ography and gravimetry we considered sham-operated mice
treated with siGFP or siMEF2C as a single control group.
Treatment with siGFP did not affect the typical changes of the left
ventricle induced by pressure overload (i.e. increases of left
ventricle thickness, cardiomyocyte diameter and interstitial
fibrosis). Pretreatment with siMEF2C retarded the load-induced
left ventricular hypertrophy as assessed by echocardiographic
determination of left ventricular wall thickness (Figure 4A).
Depletion of MEF2C did not change the left ventricular diameter
or fractional shortening (Figure 4B, C). Notably, the systolic
gradient across the aortic constriction was similar in mice injected
with siGFP or siMEF2C (Table 1). The attenuation of load-
induced left ventricular hypertrophy in mice treated with
siMEF2C was confirmed by gravimetry (Figure 4D). In addition,
siMEF2C attenuated the increases in the diameter of cardiomy-
ocytes (Figure 4E).
Representative examples of myocardial samples from sham-
operated and banded mice treated with siGFP or siMEF2C are
shown in Figure 5A–F. Left ventricular fibrosis was attenuated in
aortic-banded mice treated with siMEF2C (Figure 5G). Figure 5H
displays data of ANP (Atrial Natriuretic Peptide) transcript in the
left ventricle from sham-operated and aortic banded mice treated
with siGFP or siMEF2C. MEF2C silencing markedly attenuated
the rises of ANP transcripts in the left ventricle of banded mice.
MEF2C Depletion Is Associated with Deficiency in
Load-Induced mtDNA Content
MEF2 factors are important regulators of gene transcription
involved in cardiac mitochondriogenesis and energy metabo-
lism[20]. Mitochondrial proliferation is frequently accompanied
by a high rate of mtDNA (mitochondrial DNA) replication[21].
Conceivably, depletion of MEF2C results in changes in the
abundance of mtDNA and energy metabolism in overloaded left
ventricle. Therefore, we next examined if depletion of MEF2C
influences the rises of mtDNA copy number induced by pressure
overload in mice left ventricle. The levels of mtDNA relative to
nDNA (mtDNA:nDNA) were similar in the left ventricle of sham-
operated mice treated with siMEF2C or siGFP. Thus, the data of
these two groups were averaged for the comparative analysis with
data from aortic banded mice. As shown in Figure 6A, pressure
overload lasting for 7 and 15 days markedly increased the left
ventricular mtDNA:nDNA ratio. Depletion of MEF2C markedly
attenuated the rises of the mtDNA:nDNA ratio induced by aortic
banding.
The augmentation of mtDNA abundance during the myocardial
hypertrophic growth involves regulation of mtDNA replication by
mtTFA (mitochondrial transcription factor A) by nuclear-encoded
transcription factors (NRFs) and PGC-1 (peroxisome proliferator-
activated receptor-gamma coactivator-1) transcriptional co-activa-
tors[22,23]. Therefore, we next examined if depletion of MEF2C
could change the expression of PGC-1a in mice left ventricle. As
shown in Figure 6B, aortic constriction (1 day) induced a rapid
increase in the expression of PGC-1a, an effect that was markedly
attenuated by MEF2C depletion. Basal myocardial expression of
PGC-1a remained unchanged in sham-operated mice depleted of
MEF2C.
Given that mitochondria are the major source of energy in the
myocardium, we next examined whether changes in the levels of
mtDNA:nDNA were accompanied by changes in the myocardial
AMP:ATP ratio, as a mean to assess the energy levels of the
myocardium. Figure 6C shows a representative chromatogramused
for the detection of ATP, ADP and AMP levels of left ventricle.
MEF2C silencing did not change AMP:ATP ratio in the left
ventricle of sham operated mice, therefore data from sham-
operated mice treated with siGFP and siMEF2C were averaged.
As shown in Figure 6D, the values of myocardial AMP:ATP ratio
were found to be greater in the left ventricle of 1 and 7 day banded
mice treated with siMEF2C in comparison to those treated with
siGFP (Figure 6D). Overall, these data support the notion that
depletion of MEF2C attenuates the load-induced replication of
mtDNA and likely inmitochondrial biogenesis in miceleft ventricle,
associated to a defect in the regulation of PGC-1a expression.
MEF2C Depletion Attenuates Hypertrophy by
Modulating mTOR/S6K Pathway
Previous studies have indicated that perturbing mitochondrial
function can influence the activity of mTOR/S6 kinase, a
signaling pathway critically involved in the reactive cardiac
hypertrophy[24,25]. Therefore we next examined whether the
anti-hypertrophic effect of MEF2C depletion is related to a
defective activation of mTOR (mammalian Target of Rapamycin).
Data shown in Figure 7A indicate that aortic banding markedly
increased S6K Thr389 phosphorylation in mice left ventricle,
while depletion of MEF2C abolished this effect. The amino acid
leucine is a potent activator of mTOR complex by a pathway
distinct from TSC-2 (Tuberous Sclerosis Protein-2) complex
phosphorylation[26,27]. Thus, we reasoned that supplementation
with leucine might rescue the defective activation of mTOR/S6K
complex after depletion of MEF2C. Supplementation of leucine in
the drinking water enhanced basal phosphorylation of S6K in the
left ventricle of sham-operated mice treated with siMEF2C or
siGFP (Fig 7B). Moreover, it partially restored the phosphorylation
of S6K in the left ventricle of banded mice depleted of MEF2C, in
parallel with the restoration of the load-induced expression of
PGC-1a (Fig 7C). Finally, we found that supplementation with
leucine attenuated the anti-hypertrophic effect of MEF2C
depletion, as indicated by gravimetry and histological data shown
in Figure 7D, E. These data are consistent with the hypothesis that
a defect in the activation of mTOR/S6K pathway provides a
mechanism by which MEF2C depletion attenuates the load-
induced left ventricular hypertrophy.
Discussion
In this study, we applied RNA interference technology to define
the function of MEF2C in the adult heart. Our results demonstrate
that the depletion of MEF2C by siRNA attenuates the
hypertrophic growth of mice left ventricle in response to pressure
overload, reduces hypertrophy in cardiomyocytes and diminishes
interstitial fibrosis and attenuates the upregulation of ANP. These
effects indicate that the downregulation of pathways controlled by
MEF2C mitigates the adverse effects of pathologic cardiac
hypertrophy and remodeling. Additionally, the results of the
current study reveal that the anti-hypertrophic effects of MEF2C
depletion may be related to a defective mobilization of mTOR/
S6K by pressure overload, which may be associated with an
intricate mechanism that involves negative modulation of the
mtDNA replication and changes in myocardial energy metabolism
caused by defective activation of PGC-1a.
Myocardial MEF2C Depletion by siRNA
We observed a reduction of about 80% in the levels of
myocardial MEF2C through siMEF2C delivery via the jugular
vein. The gene silencing induced by siMEF2C was restricted to the
lung and heart, indicating the efficiency of this route to achieve
delivery of siRNA to the left ventricle, as well as the lack of
significant exposure of tissues and organs distal to the left ventricle
MEF2C and Cardiac Hypertrophy
PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8472Figure 4. MEF2C silencing prevents load-induced left ventricular hypertrophy. Data from sham operated (SO) and aortic banded mice (7 to
15 days after transverse aortic constriction – TAC). Bar graphs indicating the echocardiographic values of (A) posterior wall thickness (LVWT), (B)
diastolic diameter (LVEDD) and (C) fractional shortening (FS). The values of SO mice treated with siMEF2C or siGFP did not reach statistical
significance, so they were averaged. (D) Bar graphs show the left ventricle mass/body mass ratio and (E) the average cardiomyocytes diameter.
*p ,0.05 vs SO; # p,0.05 vs TAC 7days siGFP; { p,0,05 vs TAC 15 days siGFP. A total of 9 mice were analyzed in each subgroup.
doi:10.1371/journal.pone.0008472.g004
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confirmed to occur in cardiomyocytes harvested from mice treated
with siMEF2C, thereby demonstrating the susceptibility of this cell
type to the effects of systemically delivered siRNA. Moreover, the
specificity of MEF2C silencing was substantiated by the lack of
effects of siMEF2C on MEF2A, MEF2B or MEF2D, as well as on
the unrelated proteins FAK, JNK, SHP2 and GAPDH. The
MEF2C depletion induced by the RNAi strategy used in the
present study lasted for approximately 4 days. Such a prolonged
effect of systemically delivered siRNA was previously observed for
distinct targets in various tissues[19,28], although the underlying
mechanism remains unclear.
Table 1. Mice hemodynamics.
Vehicle Leucine
siRNA
GFP siRNA
MEF2C siRNA
GFP siRNA
MEF2C
SO TAC 7days TAC 15 days SO TAC 7 days TAC 15 days SO TAC 7days SO TAC 7days
N 11 12 7 11 7 10 9 8 7 9
SBPa(mmHg) 123631 7 1 63* 17764* 12163 17163* 17166* 138631 7 1 66# 145641 6 0 66#
SBPf (mmHg) 119621 2 8 64 124631 2 5 651 2 3 621 2 9 64
SGr 52624 9 634 6 614 6 654 8 654 3 62
HR (beats/min) 397622 420616 377626 436615 365619 365626 415615 422612 443611 40269
SO. Sham operated; TAC. transverse aorta constricted; SBPa. systolic blood pressure in ascending aorta; SBPf. systolic blood pressure in femoral artery; SGr. systolic
gradient; HR. heart rate.
*P,0.05 indicated statistical significance compared to values of SO mice treated whit vehicle.
# P,0.05 indicated statistical significance compared to values of SO mice treated whith leucine.
doi:10.1371/journal.pone.0008472.t001
Figure 5. MEF2C silencing prevents the myocardial deleterious effects of pressure overload. Myocardial samples of SO and TAC mice
treated with siMEF2C or siGFP stained with Masson trichrome (X400): (A) - SO- siGFP, (B) – SO- siMEF2C, (C) – TAC(7days)- SO- siGFP, (D) -
TAC(7days)- siMEF2C, (E) - TAC(15days)- SO- siGFP, (F) - TAC(15days)- siMEF2C. (G) Bar graph indicates the average fraction volume of collagen
(CVF%) (n=9 mice each subgroup). (H) Relative quantity (RQ) of ANP transcript (n=9 mice each subgroup). * p,0.05 compared with values of SO
mice; # p,0.05 compared with values of TAC 7days siGFP mice, { p,0,05 compared to values of TAC 15days siGFP mice.
doi:10.1371/journal.pone.0008472.g005
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A key finding in the current study is the attenuation of the load-
induced left ventricular hypertrophy induced by MEF2C silencing.
Remarkably, our results also show that depletion of MEF2C
attenuated the interstitial fibrosis and the rise of ANP expression,
without affecting the left ventricular function, indicating that
depletion of MEF2C may reduce the adverse effects of pressure
overload. Consistent with this hypothesis, data from previous
studies indicate that activation of MEF2C may mediate myocar-
dial adverse events invoked by pathological stress[8].
MEF2 transcription factors have been implicated in the direct
and indirect regulation of multiple genes[8,9]. It has been shown
that a null mutation of MEF2C affects the expression of cardiac
structural and stress response genes in developing hearts[15]. In
addition, studies that analyzed global gene expression in the left
ventricle of MEF2C transgenic mice indicated an upregulation of
genes encoding ion-handling and extracellular matrix-associated
proteins[8], which might be involved in the deleterious effects of
MEF2C activation. However, it is still uncertain whether these
genes are involved in the hypertrophic growth induced by MEF2C
activation. The data gathered in the present study reveal that
MEF2C depletion blunted the increases in mtDNA and the ability
of the myocardium to sustain the ATP levels when subjected to
pressure overload, indicating that MEF2C may play a role in
regulating the cardiac mitochondriogenesis and energetic metab-
olism in response to hypertrophic stimuli. Accordingly, we have
shown here that MEF2C depletion markedly attenuated the rise
of PGC-1a induced by pressure overload, providing an illustra-
tion of the specific contribution of the MEF2C to the control of
myocardial mitochondria and metabolism in response to mechan-
ical stress. Consistent with this, the level of PGC-1a was previously
shown to play a major role in setting the cardiac mitochondrial
content[22,23]. Furthermore, MEF2 factors have been shown to
mediate the Ca
2+/Calcineurin activation of PGC-1a promoter
and deletion of MEF2A in mice was demonstrated to result in
perturbation of mitochondrial structure[17,29]. Finally, forced
expressions of either MEF2C or PGC-1a are known to lead to
mitochondrial ultrastructural abnormalities and development of
Figure 6. MEF2C silencing negatively regulates myocardial mitochondriogenesis. (A) Bar graph shows relative quantity (RQ) of mtDNA
(mt - mitochondrial) to nDNA (n – nuclear). (B) PGC-1a protein expression. (C) Representative chromatogram of AMP, ADP and ATP detection peaks.
(D) Bar graph indicates the average values of the AMP:ATP ratio. The data were from left ventricle of SO and TAC (1 day) mice treated with siMEF2C or
siGFP (n=9 mice each subgroup).* p,0.05 compared with values of SO mice; { p,0.05 compared with values of TAC 1day siGFP mice; # p,0.05
compared with values of TAC 7days siGFP mice; { p,0.05 compared with values of TAC 15days siGFP mice.
doi:10.1371/journal.pone.0008472.g006
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PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8472Figure 7. MEF2C depletion attenuates hypertrophy by modulating mTOR/S6K pathway. (A) S6K and phosphoS6K (p-S6K) protein
expression in the left ventricle of SO and TAC (1 day) mice treated with siMEF2C or siGFP (n=6 mice each subgroup). From samples of left ventricle of
SO and TAC (7 days) mice treated with siMEF2C or siGFP and leucine (n=9 mice each subgroup) were measured: (B) S6K, phosphoS6K (p-S6K) and
(C) PGC-1a protein levels, (D) the left ventricle mass/body mass ratio mice and (E) the average fraction volume of collagen (CVF%). * p,0.05
compared with values of SO mice.
doi:10.1371/journal.pone.0008472.g007
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modulation of load-induced mitochondrial biogenesis may contrib-
ute to the beneficial effects of MEF2C depletion in overloaded
myocardium. It was somewhat surprising to find that the improved
cardiac phenotype after MEF2C, i.e. with less fibrosis and less
pathological hypertrophy, was accompanied by a transient worse
energetic profile including higher AMP/ATP levels. Although we
have no clear explanation for these effects, one could speculate they
are consistent with an expected increase in the myocardial energy
consumption induced by pressure overload in the absence of
appropriate hypertrophic growth. Maintenance of normal cardiac
function in the face of increased workload but without changes in
the left ventriclewall thickness, end-diastolic or end-systolic volumes
implies a positive inotropic effect, which is paralleled by increased
energy consumption per unit of myocardial mass. This would
explain thehigherAMP/ATP ratio ofoverloadedmiceleft ventricle
silenced for MEF2C. Moreover, these data may imply that the
activation of mitochondrial biogenesis in the early hypertrophic
responses to pressure overload might have detrimental influence on
the heart. Accordingly, increased mitochondrial mass could induce
abnormally high myocardial oxidative stress that in turn might
induce cell loss in the early period of pressure overload[30].
Alternatively, functional and structural abnormalities of mitochon-
dria from overloaded heart might be related solely to increases in
mitochondrial mass which might affect myofibrils, compromising
the contractile function[31]. Thus it is conceivable that lessening
MEF2C levels by modulating the excessive mitochondrial biogen-
esis of overloaded myocardium, may contribute to mitigate the
degeneration of overloaded myocardium. However, this issue needs
further studies.
The data from the present study indicate that MEF2C depletion is
accompanied by downregulation of the mTOR/S6K pathway
[32,33] [34]. Remarkably, the restoration of the activity of this
signaling complex after supplementation with leucine was accompa-
nied by suppression of the anti-hypertrophic of MEF2C depletion,
indicating that the defective activation of mTOR/S6K pathway is a
criticalcomponentofthebeneficialeffectsofMEF2Cdepletioninthe
cardiac phenotype of TAC mice. Conversely, the activation of this
pathway might be involved, together with changes in mitochondrial
biogenesis and function, to the detrimental effects of MEF2C
activation in cardiac hypertrophy. These assumptions are in
agreement with previous data indicating that mTOR/S6K complex
plays a crucial role in the hypertrophic growth of cardiomyocytes and
left ventricleinvoked by mechanical stress[18,35]. Moreover,mTOR
overactivation has been shown to cause increased mitochondrial
biogenesis and accumulation of reactive oxygen species in distinct
model systems[36], suggesting that the activation of mTOR pathway
might be responsible for the detrimental effects of MEF2C activation
and vice-versa to the beneficial effects of MEF2C depletion in the
mechanically overloaded hearts. However, the mechanisms that
connect the MEF2C to mTOR/S6K pathway were not explored in
the present study. It is possible that the activation of AMPK induced
by the raise in the AMP:ATP relative amount may inhibit the
mTOR/S6K complex in the overloaded myocardium[32]. Alterna-
tively, reduced mitochondrial function may also inactivate mTOR
activity[37], however further studies are needed to clarify this issue.
In conclusion, we used RNAi strategy to deplete MEF2C in the
left ventricle of adult mice and understand the role of this factor in
the responses of the left ventricle to mechanical stress. The data
indicate that depletion of MEF2C is sufficient to markedly
attenuate the hypertrophic growth and myocardial fibrosis of
overloaded left ventricle by a mechanism dependent on defective
activation of mTOR/S6K pathway. Overall, these data highlight
the potential of MEF2C in the pathogenesis of cardiac
hypertrophy and remodeling, and provide insights into novel
therapeutic targets to heart disease.
Materials and Methods
Expanded Materials and Methods are available in the
Supporting Information Text S1 file of this manuscript.
Ethics Statement
Animals were handled in compliance with the principles of
laboratory animal care formulated by the Animal Care and Use
Committee of University of Campinas. Procedures such as jugular
vein catheterization, aortic banding, echocardiographic examina-
tion and arterial vessels catheterization for blood pressure
monitoring were performed under anesthesia with a mixture of
ketamine (100 mg/Kg) and xylazine (5 mg/Kg).
Antibodies and Chemicals
Polyclonal mouse antibody against MEF2C was from Abcam
(ab43796-100). Polyclonal rabbit antibodies against FAK (sc558),
SHP2 (sc7384), JNK (sc571), GAPDH (sc25778), S6K p70 (sc230),
pS6K p70 Thr389 (sc11759R) and PGC1-a (sc13067), were
purchased from Santa Cruz Biotechnology (USA). Antibody
against MEF2A was from Cell Signaling (9736). Antibodies were
used following the manufacturer’s recommendation. Colagenase
type IA and trypsin were from Sigma (USA). Trizol, Phenol and
Super Script II were from Invitrogen. Super Signal west Pico
Cheluminescent Substract and Ampliscribe T7 high yield
transcription were from Epicentre. L-Leucine was from Ajinomoto
Aminoscience LLC.
Experimental Models and Animals
Swiss mice (6–8 week old) and neonatal Wistar rats were obtained
from the animal facility center of State University of Campinas.
Animals were handled in compliance with the principles of
laboratory animal care formulated by the university’s Animal Care
andUseCommittee.Proceduressuchasjugularveincatheterization,
aortic banding, echocardiographic examination and arterial vessels
catheterization for blood pressuremonitoring were performed under
anesthesia with a mixture of ketamine (100 mg/Kg) and xylazine
(5 mg/Kg) as previously reported[19]. Primary cultures of neonatal
rat ventricular myocytes (NRVMs) were prepared from 1- to 2-day-
old Wistar rats and plated on type I collagen Bioflex plates at
5610
5 cells/well, as previously reported[38].
Isolation of Adult Mouse Ventricular Myocytes
Mouse cardiac myocytes were isolated from mice ventricle one
day after treatment with siRNA targeted to MEF2C (siMEF2C) or
GFP (siGFP), as previously reported[19].
Echocardiography
2D M-mode echocardiography was performed with a 12-MHz
probe connected to a Toshiba Power Vision system in anesthetized
mice by a blinded observer at 15 minutes after the induction of
anesthesia, as previously reported[19]. The short axis measure-
ments were taken at the level of the midpapillary muscle. Three
measurements were taken at end-systole and end-diastole to
determine left ventricular diastolic and systolic diameter, wall
thickness and fractional shortening.
Hemodynamics
For blood pressure monitoring the right carotid and the right
femoral arteries were cannulated with flame stretched PE-50
MEF2C and Cardiac Hypertrophy
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8472polyethylene tube. Blood pressure in the carotid and femoral
arteries were simultaneously recorded for a 10 minute period to
determine the transconstriction systolic gradient. The following
parameters were computed: systemic systolic, mean and diastolic
blood pressure (mmHg) and heart rate (bpm).
Histological Examination
Hearts were rapidly excised from fully anesthetized mice and
washed in PBS. The left ventricles were fixed in 10%
paraformaldehyde, embedded in paraffin and cut into 5 mm
sections. Tissue sections stained with haematoxylin and eosin (HE)
and Masson’s trichrome underwent morphometric studies using
an image analysis system (Leica Q500 iW; Leica Imaging Systems,
Cambridge, UK).
siRNA Design and Synthesis
siRNA targeted to mouse MEF2C gene was designed and
synthesized as previously published[18,19]. DNA oligonucleotides
(IDT-USA) were as follow: (i) T7: 59-GGTAATACGACTCAC-
TATAG-39. (ii): MEF2C 1187 sense: 59-CCCACCUGGCAG-
CAAGAACAC-39 (iii): MEF2C 1187 antisense: 59-GUUCUUG-
CUGCCAGGUGGGAU-39 (iv): GFP sense: 59-GTGTCTTG-
TAGTTCCCGTCTATAGTGAGTCGTATTACC-39. (v): GFP
antisense: 59-ATGACGGGAACTACAAACACCTATAGTGA-
GTCGTATTACC-39 were ordered from IDT (USA). The
oligonucleotide-directed production of small RNA transcripts with
T7 RNA polymerase were made with Ampliscribe
TM T7
transcription kit (Epicentre Biotechnologies; Madison WI, USA)
according to manufacturer’s instructions.
Transfection of NRVMs with siRNA
NRVMs were transfected with siRNA as previously reported
[18].
Western Blotting
Tissue or cell extracts containing equal amounts of total protein
(50 mg) were resolved by 8% SDS-PAGE. The membranes were
incubated with primary antibodies. Detection was accomplished
by using an enhanced chemiluminescence detection system.
Gene Transcripts and Mitochondrial DNA Quantification
Myocardial MEF2A, MEF2C, MEF2D and ANP transcripts
were quantified after reverse transcription to cDNA followed by
real-time PCR. Primers are shown in Table S1 of Supporting
Information. Results were evaluated by the comparative CT
method in respect to GAPDH, used as the normalizer. For
mithocondrial and nuclear DNA quantification, were compared
the expression of D-loop (EU194676.1) and 18S rRNA
(NR_003278.1) genes, respectively.
Myocardial AMP and ATP
Samples of myocardium were analyzed for AMP and ATP
quantification by a method based on high performance liquid
chromatography.
Statistical Analysis
Data are presented as means6SEM. Student’s t-test and 1-way
repeated-measures ANOVA were used to compare groups. Post
hoc analysis was performed with Bonferroni multiple-range test. A
value of P,0.05 indicated statistical significance.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0008472.s001 (0.08 MB
DOC)
Table S1
Found at: doi:10.1371/journal.pone.0008472.s002 (0.04 MB
DOC)
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